GET DAILY SIGNALSWhy Is 10x Genomics (TXG) Stock Up +3.77% Today?
Key Takeaways
- TXG shares climbed 3.77% on Wednesday, rebounding to $65.27 from a prior close of $62.90.
- The advance reflects bargain hunting and a technical recovery after a sharp post-earnings selloff that erased nearly half the stock's value off its recent highs.
- Continued enthusiasm around the company's new Atera spatial-biology platform and the AI-driven biology narrative supported the recovery.
- A newly announced Xenium platform breast cancer biomarker study in China added a fresh positive headline for the life-science tools maker.
- The move aligns with a broader rebound in genomics and life-science tools names following recent volatility.
- Traders are now watching Atera shipment progress, fourth-quarter gross-margin guidance, and upcoming analyst commentary.
- For deeper detail, explore Price Targets, Earnings, and Forecast pages for TXG.
- To see which AI-powered trading strategies are performing best right now, visit the Trending AI Robots page.
Opening Summary
10x Genomics, Inc. (TXG), a Pleasanton, California-based life-science technology company that develops instruments, consumables, and software for single-cell and spatial biology, advanced 3.77% in Wednesday's session, closing at $65.27 versus a prior close of $62.90. The gain marks a continuation of a volatile recovery pattern that has defined the stock since its early-November third-quarter earnings report, which beat Wall Street expectations yet triggered a sharp selloff. Wednesday's advance reflected renewed bargain hunting, ongoing optimism around the Atera spatial platform, and a fresh product-study announcement in China.
Post-Earnings Recovery and Bargain Hunting
The clearest driver behind the move was a continued rebound from the stock's steep post-earnings decline. On November 5, the company reported third-quarter revenue of roughly $150.7 million, up 1.1% year over year and above consensus, along with a narrower-than-expected GAAP loss of $0.15 per share. Management also raised its full-year 2026 revenue outlook to $625–635 million. Despite the beat-and-raise, shares sold off because total instrument revenue fell sharply, as customers delayed purchases of existing systems while awaiting the new Atera platform. With the stock having tumbled roughly 45% from its 52-week high, Wednesday's price rally suggests investors are rotating back into the name as they reassess the growth story behind Atera.
Atera Momentum and the AI-Driven Biology Narrative
Enthusiasm for Atera, the company's whole-transcriptome spatial-profiling instrument, remained a key support for the stock. Management has described Atera as potentially the largest product introduction in company history, noting that demand has outpaced supply and that production and installation capacity—not customer interest—is the current bottleneck. Nearly all of the world's top 20 biopharmaceutical companies have purchased Atera systems or its Catalyst research services. The company has positioned its single-cell and spatial technologies as essential infrastructure for large-scale, AI-driven biological data generation, a theme that continues to resonate with investors in the genomics tools space.
Xenium China Study Adds a Fresh Catalyst
Supporting sentiment, Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center launched a breast cancer biomarker study using the company's Xenium platform. The 24-month trial aims to identify biomarkers that could predict how patients respond to neoadjuvant therapy. While not a financial event, the announcement reinforced the real-world clinical adoption of the company's spatial-biology portfolio and provided a concrete headline around expanded use of its technology in precision oncology.
Market Context and Trading Activity
The move occurred amid a broader recovery in genomics and life-science tools names, which had been pressured in recent sessions by analyst price-target cuts and concerns over near-term instrument sales. TXG has been among the most volatile stocks in its group, with frequent moves exceeding 5% over the past year. After briefly dipping below $52 in the immediate post-earnings reaction, the shares have staged an uneven recovery, bouncing roughly 10% on Monday before giving back part of that gain on Tuesday. Wednesday's advance pushed the stock back above the $65 level, a threshold that has served as a focal point for traders during the recent swings.
What Comes Next for TXG
Investors will be closely watching the ramp of Atera shipments toward the company's target of roughly 50 instruments by year-end, as well as fourth-quarter gross-margin guidance, which management has indicated will step down to the mid-60s percentage range as instrument shipments rise. The company's scheduled participation at the Jefferies Global Healthcare Conference on November 17 could provide additional color on demand trends and production capacity. Key risks include the pace of conversion from legacy instruments to Atera, competitive pressure in spatial biology, and elevated valuation multiples relative to near-term earnings. Continued insider selling and recent analyst price-target reductions also remain points of caution for traders.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a way to monitor which automated approaches are currently leading the market. Exploring this page can help you identify AI-driven signals that align with your own research and trading style.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TXG in downward trend: 10-day moving average crossed below 50-day moving average on November 02, 2026
The 10-day moving average for TXG crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for TXG moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 23 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXG as a result. In 63 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for TXG turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 34 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
TXG moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for TXG entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 210 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
TXG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.356) is normal, around the industry mean (4.142). P/E Ratio (-100.475) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a life science technology company, which engages in building products to interrogate, understand and master biology
Industry MedicalNursingServices
Advertisement